Hu X., Wang S., Fu S., Zeng J., Wu Y., Gong L., Cao Y., Zhang Y., Han Y., Ouyang H., Xiong Y., He X., Cheng J., Zou S., Chen Z., Tao L., Meng J., Huang L., Yuan Q., Peng Z., Li Q. Discovery of XRF-1021, a 2,4-disubstituted-5-fluoropyrimidine derivative as a homeodomain-interacting protein kinase 2 inhibitor for the treatment of chronic kidney disease. Eur J Med Chem, 2026, 302(Pt 2): 118353.
Hits:
|
Pre One:Zhao R., Zhao C., Gao R., Cai Q., Li Q., Hu L. Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics. Drug Discov Today, 2025, 30(1): 104287.
Next One:Yao M., Wu Y., Hu X., Feng C., Xu J., Chen Z., Li Q. Design, synthesis, and in vitro anti-renal fibrotic effects of imidazopyridazine-based homeodomain-interacting protein kinase 2 inhibitors. Bioorg Med Chem, 2026, 132: 118456.
